GlassScriptPhysician profile
Pablo W Concepcion
NPI 1043232432
$5,482.11
in general payments reported to CMS, 2019-2025
29 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $463 · 2021: $703 · 2022: $799 · 2023: $758 · 2024: $1,227 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,507.46 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Abbott Laboratories | $698.74 | 2019-2025 | Eterna |
| Medtronic, INC. | $454.21 | 2021-2024 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Accurian |
| Mml US, INC. | $288.30 | 2023 | Reactiv8 |
| Abbvie INC. | $240.45 | 2019-2025 | Botox, Ubrelvy |
| Medtronic USA, INC. | $196.70 | 2019-2020 | |
| Relievant Medsystems, INC. | $167.01 | 2022 | |
| Allergan, INC. | $147.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.17 | 2019 | |
| Nevro Corp. | $115.08 | 2019-2024 | Senza |
| Fidia Pharma USA INC. | $103.50 | 2019-2021 | |
| Lilly USA, LLC | $66.30 | 2019 | |
| Spr Therapeutics, INC | $63.60 | 2019-2023 | Sprint Pns System |
| Nalu Medical, INC. | $37.39 | 2021-2025 | Nalu Neurostimulation System |
| Globus Medical, INC. | $33.33 | 2025 | Senza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $26.82 | 2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $26.05 | 2019 | |
| Pfizer INC. | $25.89 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $22.05 | 2023 | Xtampza |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $18.71 | 2025 | Zilretta, Iovera |
| Impel Pharmaceuticals INC. | $15.26 | 2023 | Trudhesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2025 | Relistor |
| Amgen INC. | $14.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.67 | 2021 | |
| Stimwave Technologies Incorporated | $13.16 | 2020 | |
| Neuronetics, INC. | $12.25 | 2022 | |
| Biodelivery Sciences International, INC. | $11.31 | 2019 | |
| Horizon Therapeutics Plc | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Concepcion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.